Fig. 2: Injection of OVA-expressing CD47KO cells induces OVA-specific antitumor responses.
From: Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
a C57BL/6 mice received intrasplenic injection of PBS (n = 11) or splenocytes from WT (n = 6) or CD47KO (n = 15) OVA-Tg C57BL/6 mice, followed 7 days later by injection (i.v.; 2.5 × 106) of EG7 cells. b C57BL/6 mice received intravenous (i.v.; n = 9) or intrasplenic (i.s.; n = 6) injection of CD47KO OVA-Tg splenocytes, or intrasplenic injection of PBS (Ctrl; n = 5), followed 7 days later by injection (i.v.) of 2.5 × 106 EG7 cells. c C57BL/6 mice were pre-inoculated intravenously with 1 × 105 EG7 cells, followed 1 day later by injection (i.s.) with PBS (n = 10) or CD47KO OVA-Tg splenocytes (n = 10). d, e CD47KO OVA-Tg splenocyte-vaccinated B6 mice that survived first EG7 challenge (CD47KO) were re-challenged (i.v.) with 2.5 × 106 EG7 (n = 10; d) or EL4 (n = 8; e) tumor cells. Controls are age-matched B6 mice challenged with EG7 (n = 10; d) or EL4 (n = 5; e) tumor cells. Source data are provided as a Source Data file.
